Report
Sun Pharma signs exclusive deal for cholesterol drug lerodalcibep
The Economic Times reports that Sun Pharma’s agreement with LIB Therapeutics covers markets worldwide except the US and China. The once-monthly PCSK9 inhibitor will be marketed as Lyrokaul in Europe.
TLDR
The Economic Times reports that Sun Pharma signed an exclusive agreement with LIB Therapeutics for lerodalcibep, a once-monthly cholesterol-lowering medication. The deal covers all markets except the US and China, and the drug will be marketed as Lyrokaul in Europe.
Combined views
10.1K
2 Sources, first seen ago
